Epoetin Alfa Therapy for Non-Dialysis Patients with Severe Anemia

Initial Assessment and Therapy Initiation

For a non-dialysis patient with a hemoglobin level of 7.0 g/dL, initiate epoetin alfa therapy after correcting iron stores and addressing other reversible causes of anemia, with a target hemoglobin of 10-11 g/dL to reduce transfusion requirements while avoiding cardiovascular risks 1, 2, 3
Confirm iron stores are adequate before initiating therapy, with transferrin saturation and ferritin checked 1, 2
Rule out other reversible causes of anemia, such as B12/folate deficiency or bleeding 2

Monitor hemoglobin levels every 2-4 weeks initially, and adjust dose to maintain hemoglobin between 10-11 g/dL 1, 2, 3, 4
Evaluate baseline blood pressure, as epoetin alfa can increase hypertension 2

Target hemoglobin level is 10-11 g/dL, as higher targets have been associated with increased cardiovascular risks and mortality 1, 2, 3, 5
Consider red blood cell transfusion rather than epoetin alfa therapy if immediate correction of anemia is needed 6, 7

If hemoglobin exceeds 11 g/dL, reduce dose or temporarily hold therapy 1, 2
If hemoglobin increases less than 1 g/dL after 4 weeks, increase dose by 25% 4
Discontinue therapy if patient develops pure red cell aplasia, severe hypertension, or serious adverse events potentially related to epoetin alfa therapy, or if hemoglobin consistently exceeds target range despite dose reductions 1, 2